|
| 32776456 | Surgical management of extremity rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, the European Pediatric Soft-Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. | Pediatr Blood Cancer | 2023 |
| 36346688 | Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group. | Clin Cancer Res | 2023 |
| 37750583 | Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report. | J Am Heart Assoc | 2023 |
| 37829670 | Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspective. | EJC Paediatr Oncol | 2023 |
| 36779385 | Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology. | J Surg Oncol | 2023 |
| 37283290 | A pilot study evaluating the use of sirolimus in children and young adults with desmoid-type fibromatosis. | Pediatr Blood Cancer | 2023 |
| 36951526 | Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group. | J Natl Cancer Inst | 2023 |
| 37267580 | The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. | J Clin Oncol | 2023 |
| 37015036 | Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents. | J Clin Oncol | 2023 |
| 37194615 | TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report. | Pediatr Blood Cancer | 2023 |
| 37441939 | Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2023 |
| 37433635 | Children's Oncology Group's 2023 blueprint for research. | | 2023 |
| 37228094 | Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. | J Natl Cancer Inst | 2023 |
| 36724417 | Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. | J Clin Oncol | 2023 |
| 36662819 | National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). | Clin Cancer Res | 2023 |
| 37542143 | Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy. | Sci Rep | 2023 |
| 32762004 | Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Soft-Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe. | Pediatric Blood and Cancer | 2023 |
| 32918788 | Introducing INSTRuCT: An international effort to promote cooperation and data sharing. | Pediatric Blood and Cancer | 2023 |
| 35137727 | Is Detection of Relapse by Surveillance Imaging Associated With Longer Survival in Patients With Rhabdomyosarcoma? | J Pediatr Hematol Oncol | 2022 |
| 36250420 | Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy. | Cancer | 2022 |
| 35969120 | Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT). | Pediatr Blood Cancer | 2022 |
| 35839732 | Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. | Eur J Cancer | 2022 |
| 35452896 | Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis. | Eur J Cancer | 2022 |
| 35870472 | Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. | Lancet Haematol | 2022 |
| 35482017 | An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report. | Cancer | 2022 |
| 35363510 | Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. | J Clin Oncol | 2022 |
| 36198128 | Automated Ascertainment of Typhlitis From the Electronic Health Record. | JCO Clin Cancer Inform | 2022 |
| 35863108 | Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 35353553 | Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. | J Clin Oncol | 2022 |
| 34623638 | Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. | Cancer | 2022 |
| 34515544 | Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. | Journal of Adolescent and Young Adult Oncology | 2022 |
| 35253352 | Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. | Pediatric Blood and Cancer | 2022 |
| 34840026 | Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 34713899 | Clinical Outcomes of Diffuse Sclerosing Variant Papillary Thyroid Carcinoma in Pediatric Patients. | Laryngoscope | 2022 |
| 35129294 | An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. | Pediatric Blood and Cancer | 2022 |
| 34652968 | Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. | J Clin Oncol | 2021 |
| 34166060 | Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. | J Clin Oncol | 2021 |
| 33522706 | Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. | Pediatric Blood and Cancer | 2021 |
| 33989020 | The Care of Children With Cancer During the COVID-19 Pandemic. | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting | 2021 |
| 34245211 | Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. | Pediatric Blood and Cancer | 2021 |
| 33915882 | Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. | J Clin Med | 2021 |
| 33548339 | Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Childrens Oncology Group. | Int J Radiat Oncol Biol Phys | 2021 |
| 33372952 | Germline Cancer Predisposition Variants inâ¿¿Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. | J Natl Cancer Inst | 2021 |
| 33306276 | Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. | Pediatr Blood Cancer | 2021 |
| 33245207 | Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. | Pediatr Blood Cancer | 2021 |
| 33302115 | The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group. | Eur J Cancer | 2021 |
| 33079399 | Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group. | Cancer | 2021 |
| 33289920 | SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. | Cancer | 2021 |
| 33340280 | Metabolic response as assessed by F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma | Cancer Medicine | 2021 |
| 33216382 | Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. | Cancer | 2021 |